Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Raj Mehra J.D., Ph.D. | CEO, Founder, President & Chairman | 599.53k | -- | 1960 |
| Mr. Michael J. Golembiewski | Chief Financial Officer | 388.2k | -- | 1971 |
| Mr. Anthony Marciano | Chief Communications Officer | -- | -- | -- |
| Mr. Gopal Krishna Ph.D. | Head of Manufacturing & Technical Operations | -- | -- | -- |
| Tim Whitaker M.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Karen Fusaro | Senior VP & Head of Clinical Operations | -- | -- | -- |
Seelos Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 8
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Corporate Governance
Upcoming Events
April 16, 2025 at 8:00 PM UTC - April 17, 2025 at 8:00 PM UTC
Seelos Therapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available